MiRNA analysis of human peritoneal dialysis effluent cells treated with or without alanyl-glutamine supplemented peritoneal dialysis fluid in a randomized controlled cross-over pilot study
Ontology highlight
ABSTRACT: The impact of PDF supplementation with alanyl-glutamine (AlaGln) on peritoneal immune-competence in 6 patients in an open-label, randomized, crossover pilot trial (EudraCT 2012-004004-36) was tested by relating functional test results to transcriptome changes (RNAseq and miRNA analysis) in PD effluent cells.
Project description:The impact of PDF supplementation with alanyl-glutamine (AlaGln) on peritoneal immune-competence in 6 patients in an open-label, randomized, crossover pilot trial (EudraCT 2012-004004-36) was tested by relating functional test results to transcriptome changes (RNAseq and miRNA analysis) in PD effluent cells.
Project description:The complete systemic deregulated biological network in peritoneal dialysis (PD) patients is still only partially defined. High-throughput/omics techniques may offer the possibility to analyze the main biological fingerprints associated with this clinical condition. For the transcriptomic part of the study, we analyzed new data from 10 patients undergoing peritoneal dialysis .
Project description:Purpose of our study is to determine the status of synaptosomal microRNAs in Alzheimer's disease and their roles in Alzheimer's progression.
Project description:For Pom pharmacogenomic study, gene expression profiling (GEP) analyses were performed on samples from 18 patients, all of whom had received prior treatment with Len and Bor. CD138-purified plasma cells were collected from patients prior to and 48 hours after the first dose of Pom (4.0 mg/d for 2 days) and samples were hybridized to Affymetrix U133Plus2.0 arrays according to the manufacturer's recommendations. For Bor study, GEP analyses were performed on samples from 25 previously treated patients on Total Therapy 6 (TT6) trial using Affymetrix U133Plus2.0 arrays. Samples were collected prior to and 48 hours post a test dose Bor (1.0mg/m2).
Project description:Here we demonstrate for the first time evidence of lineage switch from B-1 B lymphocyte to a macrophage , or so-called transdifferentiation, occurring in mature cells in vivo. Specifically, using transgenic B6.Mb1-iCre/Rosa26-YFP mice, in which YFP expression is restricted exclusively to B cell lineage, we discovered that a significant portion of tissue-resident macrophages in peritoneum, pleural cavity and intestine in steady state are positive for YFP. B cell origin of YFP+ macrophages was confirmed by next-generation sequencing of genomic DNA locus encoding immunoglobulin heavy chain genes. Eliciting a self-resolving zymosan peritonitis showed that during inflammation a subset of B-1 B cells gives rise to inflammation-induced macrophages. The aim of this study was to perform transcriptome analysis of B-1 B cell-derived macrophages (B-1/macrophages) from the naM-ove and inflamed murine peritoneum and compare them to already established populations of naM-ove tissue-resident macrophages, inflammation-experienced resident (yolk-sac-derived) macrophages and inflammation-induced (monocyte-derived) macrophages.
Project description:Transcriptome analysis of two population of peritoneal mononuclear phagocytes (CD14+ macrophages and CD1c+ dendritic cells) in peritoneal dialysis effluent from stable (infection-free) peritoneal dialysis patients.
Project description:Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. The initial treatment of lung cancer depends on the definition of the tumor type and its staging. The most common treatment is chemotherapy, and the first-line treatment is a combination of carboplatin and paclitaxel. Although this treatment has good efficacy, there is a high prevalence of adverse reactions, especially hematological reactions. Studies on new biomarkers related to these adverse reactions, such as circulating miRNAs, are very important for optimizing the quality of life of patients. miRNAs have high stability in several biological fluids and they have specific expressions in different tissues or pathologies. Thus, this study aimed to verify the relationship between circulating miRNAs and adverse hematologic reactions caused by treatment with carboplatin and paclitaxel in patients with lung cancer. miRNAs were extracted from samples collected from six patients without anemia and six patients with anemia using the miRNeasy Serum/Plasma Kit (Qiagen, cat no. 217184). After miRNA extraction, microarray analysis was performed. The samples went through processes of marking, insertion in the chips, hybridization for 18 h, washing, and scanning. All procedures were performed using the Affymetrix multi-user platform®, and were in accordance with the user guide of the commercial kit MicroArrayFlashTag™Biotin HSR RNA Labeling Kit Genechip®4.0 (ThermoFisher, Cat No. /ID: 902445,900720,900454).
Project description:Total RNA was extracted from monocyte and macrophages isolated from the peritoneal cavity of un-inflamed mice or 4, 24, 48 an 72h after mice had been injected with 0.1 or 10mg zymosan
Project description:The STAyCIS trial is a randomized, double-blind, placebo-controlled, multicentre study evaluating the efficacy and safety of atorvastatin (Lipitor, Pfizer, 80mg/day) in patients with clinically isolated syndrome (a first demyelinating event) and at high risk of conversion to relapsing, remitting multiple sclerosis (RRMS). Samples were obtained from subjects in the STAyCIS study (NCT00094172) within a screening phase of 90 days from the index CIS event and followed up for 18 months (12 months treatment phase) with serial clinical and radiological (MRI imaging) review. The primary combined endpoint was the development of either radiological (>=3 new T2 MRI lesions) or clinical relapse (>=1 clinical exacerbation) during the 12 month treatment phase. Frozen, viable PBMC were stored before thawing and extraction of CD8+ cells by positive magnetic bead selection. RNA extracted from viable, purified CD8+ cells was labelled and hybridized to Affymetrix HuGene-1_0-st-v1 arrays.
Project description:To acquire a better understanding of the molecular pathogenesis of HS, we performed mRNA microarray studies to compare gene expression in lesional skin to healthy skin of HS patients. A significant difference was observed in mRNA expression between lesional and clinically healthy skin of HS patients. Skin biopsy samples (n=30, LS: lesion, NL: non-lesion) were collected at baseline from patients with hidradenitis for RNA extraction and microarray analysis.